Common Side Effects of Lurbinectedin
Lurbinectedin (Zepzelca), approved for small cell lung cancer after platinum chemotherapy, causes myelosuppression as its primary toxicity. Neutropenia affects 66% of patients (grade 3/4 in 51%), anemia 46% (25% severe), and thrombocytopenia 37% (17% severe). Fatigue occurs in 50%, nausea in 37%, decreased appetite in 33%, and vomiting in 22%. These stem from its mechanism inhibiting DNA repair in cancer cells, also impacting bone marrow.[1][2]
Severe or Serious Risks
Grade 3/4 adverse events include febrile neutropenia (7%), pneumonia (6%), and dyspnea (5%). Rhabdomyolysis, hepatotoxicity, and tumor lysis syndrome are rare but reported. Premedication with dexamethasone reduces hypersensitivity. Discontinue if severe myelosuppression persists or for grade 4 non-hematologic toxicity. Monitor CBC weekly and liver enzymes.[1][3]
How Side Effects Compare to Similar Treatments
Compared to topotecan (another SCLC drug), lurbinectedin shows higher neutropenia (51% vs. 70% grade 3/4) but lower severe anemia and thrombocytopenia. Real-world data confirm similar profiles, with G-CSF use mitigating neutropenia in 20-30% of cases.[2][4]
Patient Management and Warnings
Hold doses for ANC <1,000/μL or platelets <75,000/μL. Avoid live vaccines and strong CYP3A inhibitors, which increase exposure. Pregnancy contraindicated (Category D); use contraception. Most effects are reversible with dose adjustments.[1][3]
Sources
[1]: FDA Label for Zepzelca
[2]: Clinical Trial Data (PMCID: PMC8253833)
[3]: Drugs.com Side Effects
[4]: ASCO Post Analysis